BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Neviani et al., [42] demonstrated that PP2A-activating agents such as FTY720 selectively reduced survival and self-renewal of TKI-resistant CML stem cells, through BCR/ABL kinase-independent pathway.